Last updated on September 2018

Phase 2b Study to Evaluate the Efficacy and Safety of GBR 830 in Adults With Moderate to Severe Atopic Dermatitis


Brief description of study

Phase 2b, randomized, double-blinded, placebo-controlled dose range finding study to evaluate the efficacy, safety and tolerability of GBR 830 in adults with moderate to severe atopic dermatitis.

Clinical Study Identifier: NCT03568162

Find a site near you

Start Over

Glenmark Investigational Site 117

Verona, NJ United States
0.41miles
  Connect »